Should follow-up cystoscopy in bacillus calmette-guérin-treated patients continue after five tumour-free years?

European Urology

Volumn 61, Issue 3, 2012, Pages 503-507

  Holmäng, Sten ^a   Ströck, Viveka ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Long term prognosis; Recurrence

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CYSTECTOMY; CYSTOSCOPY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CYSTOSCOPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84856395200     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.11.011     Document Type: Article

References (10)

1. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
2. H.W. Herr Tumor progression and survival of patients with high grade, non-invasive papillary (TaG3) bladder tumors: 15-year outcome J Urol 163 2000 60 62
3. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124 1129 (Pubitemid 30169376)
4. T. Grdmark, S. Jahnson, R. Wahlqvist, H. Wijkström, and P.-U. Malmström Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk BCa BJU Int 99 2007 817 820 (Pubitemid 46439578)
5. D. Margel, T. Raanan, S. Golan, D. Kedar, D. Engelstein, and J. Baniel Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guerin immunotherapy Urology 69 2007 78 82 (Pubitemid 46161685)
6. K. Matsumoto, E. Kikuchi, and Y. Horiguchi Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods Urology 75 2010 1385 1391
7. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
8. P. Andius, M. Fehrling, and S. Holmäng Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects BJU Int 96 2005 1290 1293 (Pubitemid 41743926)
9. H.W. Herr, S.M. Donat, and V.E. Reuter Management of low grade papillary bladder tumors J Urol 178 2007 1201 1205 (Pubitemid 47368408)
10. H. Boman, H. Hedelin, and S. Holmäng Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrences J Urol 167 2002 80 83 (Pubitemid 34024504)